Weight in Biological Technology

Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity

... doses, experienced significantly more weight loss on average (11%; 22 pounds, p<0.01) than ... role of leptin in regulating body fat, the weight loss in these patients was predominantly due to a ... combination arms achieved more weight loss than placebo. The magnitude ...

New Drug Application for Exenatide Once Weekly Accepted for Review by FDA

... are considered obese.(v) Data indicate that weight loss (even a modest amount) supports patients in ... metformin or a thiazolidinedione, with potential weight loss. BYETTA is not a weight loss product. BYETTA was approved in April 2005 ...

Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions

... in fasting plasma glucose, HbA1c and body weight during 28-day treatment NEW ORLEANS, June 8 ... reductions. HbA1c & Body weight ITCA 650 Dose Arms ... -0.62 -0.45 -0.58 Mean change in weight (kg) -0.28 -0.31 -0.93 -2.91 ...

Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions

... as previously reported results on the primary weight loss endpoints and measures of cardiometabolic ... results show that Contrave initiates and sustains weight loss and can improve predictive markers for heart ... U.S. centers. The trial evaluated the additional weight loss of Contrave (32mg naltrexone SR/360mg ...

Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings

... + Bupropion Combination Causes Significant weight Loss: A 56-week Phase 3 Study" Time: 9:00 ... Title: "Naltrexone + Bupropion Combination Causes weight Loss and Improves Quality of Life" Time: ... + Bupropion Combination Causes Significant weight Loss Without Worsening Psychiatric Symptoms" ...

Data on VIVUS' Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting

... Previous studies have shown significant weight loss with Qnexa treatment. Both podium presentations will highlight the benefit of weight loss and the corresponding positive impact on ... from the phase 3 EQUATE trial (OB-301) shows that weight loss with Qnexa stops the progression of type 2 ...

Arena Pharmaceuticals Announces First Quarter 2009 Financial Results

... lorcaserin patients lost 5% or more of their body weight from baseline, compared to 20.3% in the placebo ... rapidly lost a medically important amount of weight in a well-tolerated manner, with about one-third losing at least 5% of their body weight in only eight weeks. Lorcaserin helped nearly ...

Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results

... with placebo. In addition, in the categorical weight reduction analysis, the percentage of patients who lost ¿10% of their body weight was 41.5% in the Contrave group compared to 20.2% ... of which is designed to measure change in body weight after 56 weeks of treatment, are expected to be ...

Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes

... and BYETTA were both associated with an average weight loss of 8 pounds from baseline. The most commonly ... 2 diabetes manage blood sugar, with potential weight loss and less frequent dosing, could offer an ... are considered obese.(v) Data support that weight loss (even a modest amount) supports patients in ...

Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events

... to treat type 2 diabetes with glucose control and weight loss. This could offer a unique value proposition ... are considered obese.(v) Data support that weight loss (even a modest amount) supports patients in ... metformin or a thiazolidinedione, with potential weight loss. BYETTA is not ...

Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis

... 2007-08 season. Pisani experienced significant weight loss, fatigue and found it extremely difficult to ... disease may lead to loss of appetite, subsequent weight loss, and fatigue. UC is a chronic disease, and ... tenderness, persistent diarrhea, rectal bleeding, weight loss and fever. There is currently no cure for ...

Surgeons Perform First Incisionless Bariatric Procedure in the United States

... McArthur of Georgetown, who has been battling her weight for more than 15 years. McArthur learned of the ... Center, which offers a comprehensive approach to weight loss, including the latest in minimally invasive ... changes in order to see and maintain significant weight loss. The procedure appealed to her because it ...

Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints

... with placebo. In addition, in the categorical weight reduction analysis, the percentage of patients who lost greater than or equal to 10% of their body weight was 20.2% in the placebo group compared to 41.5% ... FDA efficacy benchmark for clinically significant weight loss. All of these findings were highly ...

Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)

... Contrave is an investigational oral weight loss medication with a mechanism of action that ... is believed to initiate and sustain significant weight loss over one year of treatment we believe by ... and allowing the body to continue losing weight by offsetting its natural tendency to fight back ...

Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results

... of OREX-003 in mitigating drug-associated weight gain and other metabolic consequences commonly ... Empatic demonstrated up to 15% reduction in body weight of healthy obese people who completed 48 weeks ... early response tended to predict longer term weight loss among the majority of study completers. ...

Intensive Lifestyle Intervention Program for Overweight or Obese Patients with Nonalcoholic Steatohepatitis Reduces Weight and Improves Overall Liver Health

... liver disease. Researchers tested the effects of weight reduction using a state-of-the-art ... exercise habits with a goal of producing a 7-10% weight loss. Participants were seen weekly in small ... "We were extremely encouraged by the results. weight loss through lifestyle intervention program ...

Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009

... Towards the end of Fiscal 2008, the weight of distributed product sales significantly ... 2008. The decreases were primarily due to the weight of increased sales of distributed products versus ... 2008. The decreases were primarily due to the weight of increased sales of Para IV products, which ...

New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes

... and dyspepsia. Patients on both treatments lost weight during the study. Weight reduction in patients on ... 35* 21 weight change, kg from baseline ... meals only if blood glucose levels are elevated. weight loss with liraglutide is attributed to the fact ...

FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania

... (37% vs. 7%), increased appetite (12% vs. 6%), weight gain (7% vs. 1%), dyspepsia (7% vs. 1%), and ... (10% vs. 4%), constipation (10% vs. 3%), weight gain (7% vs. 1%), dysarthria (5% vs. 0%), and ... 4-11%), orthostatic hypotension (7% vs. 5%), weight gain (7% vs. 1%), increased appetite (12% vs. ...

Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain

... of OREX-003 in mitigating drug-associated weight gain and/or other metabolic consequences commonly ... demonstrated that zonisamide mitigated both weight gain and elevated blood glucose associated with ... of achieving appetite suppression and sustained weight loss. Beyond obesity, Orexigen is developing ...

Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants

... IGFBP-3 complex administered to very low birth weight infants." "The possibility of preventing ROP ... from 26 weeks + 0 days to 29 weeks + 1 day (birth weight 810-1,310 g). Treatment with IPLEX(TM) took place ... babies are at risk for ROP, and very low birth weight is an additional risk factor. About Premacure ...

alli(TM) Partners with Breast Cancer Network of Strength(TM) to Support Women Challenged by Breast Cancer, Weight Loss or Both

... word is getting out about the link between excess weight and breast cancer, women need support to not only ... of the way." Women Reduce Cancer Risk, Lose weight with alli More than four million Americans have lost weight with alli during the past year. Many of those ...

Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA

... or a thiazolidinedione, and progressive weight loss. BYETTA was approved in April 2005 and has ... are considered obese.(6) Data support that weight loss (even a modest amount) supports patients in ... JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with ...

OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003

... Less Potential for Treatment-Associated weight Gain and Metabolic Risks SAN DIEGO, July 29 ... that it hopes would minimize the potential for weight gain or other adverse metabolic consequences ... that the addition of zonisamide prevented weight gain and elevated blood glucose associated with ...

Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009

... paths of development. During Fiscal 2008, the weight of distributed product sales significantly ... 2008. The decrease was primarily due to the weight of increased sales of distributed products versus ... 2008. The decrease was primarily due to the weight of increased sales of Paragraph IV products ...

Studies Show USGI Medical's EndoSurgical Operating System(TM) Enables Incisionless Surgery to Reduce Gastric Pouch and Stoma After Gastric Bypass

... pouch and stoma in patients who've regained weight after initial success with gastric bypass. ... patients in the study all had lost significant weight after gastric bypass, but slowly began to regain weight over time," Herron, Chief of Bariatric Surgery at ...

Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008

... Elicits Sustained Glycemic Control and weight Loss Over 52 Weeks" will be presented by John B. ... PT (7:30 PM ET). Obesity 1. Poster: "Enhanced weight Loss Following Pramlintide/Metreleptin ... PM PT (3:00 - 5:00 PM ET). 2. Oral: "Enhanced weight Loss Following Co-Administration of Pramlintide ...

MannKind Corporation Response to Recent Market Events

... ability to optimally treat their disease. -- No weight gain and even weight loss in patients treated with Technosphere(R) Insulin, in contrast to the weight gain that is usually considered a major ...

Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results

... in key growth areas related to obesity and weight management, and gastric cancer. "We are ... making good advances on the development of our weight loss test and expect to begin studies in medical weight loss clinics in the U.S. in 2008." Research and ...

Salugen's Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis

... two years, Salugen's research around genetics and weight loss has been repeatedly awarded by the nation's ... a DNA-customized nutritional supplement for weight management, is a potentially effective agent in reducing weight and improving symptomatic RDS behaviors. We ...

The sensitive side of carbon nanotubes: Creating powerful pressure sensors

... block would be able to detect very slight weight changes and would be beneficial in any number of ... sensor would function similarly to a typical weight scale. By placing an object with an unknown weight onto the carbon nanotube block, the block would ...

New Data Reveal Ethnicity May Play Role in Weight Loss Decisions

... -- A new analysis of a landmark weight loss survey suggests that Hispanics and African ... whites to use unproven dietary supplements for weight loss. The data, presented today at the 2007 ... research that more awareness about recommended weight loss treatments and the associated health risks ...

Salugen Expands U.S. Distribution and Announces a Partnership with DNA Dimensions to Bring DNA Customized Nutritional Solutions to Metro Detroit Area

... a DNA-customized nutritional solution for weight management, along with other products ... and energy levels which results in sustainable weight loss. GenoTrim is now available through DNA ... relationships, Ancestry, Forensics, and now, weight Control. Test results are fast, accurate, and ...

Salugen Announces the U.S. Launch of GenoTrim - a DNA Customized Nutritional Solution for Weight Management

... of GenoTrim, a DNA-based nutritional solution for weight management*. Attempts to achieve a healthy weight through both standard weight reduction strategies and numerous "gimmicks" have ... and body composition that may contribute to the weight challenges of many of these individuals. ...

Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review

... as a safe and effective treatment option for weight loss. We are also looking forward to additional ... this promising compound, which seeks to address weight loss by selectively stimulating a specific area ... significant, progressive and dose-dependent weight loss over a 12-week period. Lorcaserin was ...

Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review

... as a safe and effective treatment option for weight loss. We are also looking forward to additional ... this promising compound, which seeks to address weight loss by selectively stimulating a specific area ... significant, progressive and dose-dependent weight loss over a 12-week period. Lorcaserin was ...

New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome

... of antithrombotic agents known as low-molecular weight heparin (LMWH). The no. 1 selling low-molecular weight heparin in the world, Lovenox(R) is obtained ... et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with ...

SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia

... percent) during the one year treatment period were: insomnia, somnolence, weight increase, anxiety, headache, weight decrease, akathisia, diarrhea, dizziness, fatigue, nasopharyngitis, blood ...

REMERON(R) Now Approved in Japan for the Treatment of Depression in Adult Patients

... Tablets therapy were: somnolence (54%), increased appetite (17%), weight gain (12%), and dizziness (7%). In short-term clinical trials, 10.4% of ... open-label treatment, 8% of patients discontinued therapy due to weight gain.(2) Full Prescribing Information is available at ...

Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting

... syndrome; tardive dyskinesia; hyperglycemia and diabetes mellitus; weight gain; seizures; orthostatic hypotension and syncope; leukopenia, ... nasal congestion, orthostatic hypotension, somnolence, tachycardia, and weight increased. For more information on Fanapt(TM), please visit the ...